Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2006
Single-dose lopinavir-ritonavir acutely inhibits insulin-mediated glucose disposal in healthy volunteers.
Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00525239 (HIV Antiretroviral Drugs and Metabolism), which is not on this map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
HIV Antiretroviral Drugs and Metabolism
Who cites it
24 citing papers in PubMed, 52 citations in OpenAlex.
- Boosting dose ritonavir does not alter peripheral insulin sensitivity in healthy HIV-seronegative volunteers.Journal of acquired immune deficiency syndromes (1999) · 2010Trial
- Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers.AIDS (London, England) · 2007Trial
- Prevalence of severe cardiovascular abnormalities amongst West African HIV-infected patients on antiretroviral therapy followed at a referral HIV centre.Southern African journal of infectious diseases · 2021Article
- COVID-19 and diabetes mellitus: from pathophysiology to clinical management.Nature reviews. Endocrinology · 2021Review
- Dissecting the interaction between COVID-19 and diabetes mellitus.Journal of diabetes investigation · 2020Review
- Metabolic and Cardiac Adaptation to Chronic Pharmacologic Blockade of Facilitative Glucose Transport in Murine Dilated Cardiomyopathy and Myocardial Ischemia.Scientific reports · 2018Article
- Hemeoxygenase-1 as a Novel Driver in Ritonavir-Induced Insulin Resistance in HIV-1-Infected Patients.Journal of acquired immune deficiency syndromes (1999) · 2017Article
- Lopinavir/Ritonavir Impairs Physical Strength in Association with Reduced Igf1 Expression in Skeletal Muscle of Older Mice.Journal of AIDS & clinical research · 2013Article
- Association of lopinavir concentrations with plasma lipid or glucose concentrations in HIV-infected South Africans: a cross sectional study.AIDS research and therapy · 2012Article
- The burden of diabetes and hyperlipidemia in treated HIV infection and approaches for cardiometabolic care.Current HIV/AIDS reports · 2012Review
- Lipodystrophy defined by Fat Mass Ratio in HIV-infected patients is associated with a high prevalence of glucose disturbances and insulin resistance.BMC infectious diseases · 2012Article
- Cardiovascular disease in HIV infection.Current opinion in HIV and AIDS · 2011Review
- Molecular mechanisms for insulin resistance in treated HIV-infection.Best practice & research. Clinical endocrinology & metabolism · 2011Review
- GS-8374, a novel HIV protease inhibitor, does not alter glucose homeostasis in cultured adipocytes or in a healthy-rodent model system.Antimicrobial agents and chemotherapy · 2011Article
- Effects of the HIV protease inhibitor ritonavir on GLUT4 knock-out mice.The Journal of biological chemistry · 2010Article
- The consequences of HIV infection and antiretroviral therapy use for cardiovascular disease risk: shifting paradigms.Current opinion in HIV and AIDS · 2009Review
- Morphologic and metabolic abnormalities in vertically HIV-infected children and youth.AIDS (London, England) · 2009Article
- Article
- The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications.Toxicologic pathology · 2009Review
- HIV protease inhibitors and insulin resistance: lessons from in-vitro, rodent and healthy human volunteer models.Current opinion in HIV and AIDS · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Previously, we found that 4 weeks of treatment with lopinavir-ritonavir did not decrease insulin sensitivity but did increase adiponectin levels. In the present study, a single dose of lopinavir-ritonavir decreases insulin sensitivity but does not alter adiponectin levels. Insulin resistance from protease inhibitors may decrease with prolonged use; an increase in adiponectin levels may mediate this effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.